Article Sidebar
Published:
Jan 12, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Evaluation of neuroprotective properties of two synthetic prenylated xanthone analogues against paraquat and 6- hydroxydopamine toxicity in human neuroblastoma SHSY5Y cells
Abstract
Purpose: To investigate whether two synthetic prenylated xanthone analogues - 1,3,6,8-tetrahydroxy- 9H-xanthen-9-one (SX1) and 1,3,6-trihydroxy-2-(3-methylbut-2-enyl)-9H-xanthen-9-one (SX2) - are potential candidates for neuroprotection against paraquat- and 6-hydroxydopamine (OHDA)-induced human neuroblastoma SH-SY5Y cell death.
Methods: SH-SY5Y cells were treated with SX1 and SX2, and the maximum non-toxic dose (MNTD) were obtained by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. MTT assay was also used to assess the ability of MNTD and half MNTD (HMNTD) doses of SX1 and SX2 to protect against the neurotoxicity of 200 μM paraquat and 100 μM 6-OHDA. Intracellular ROS production by SHSY5Y cells treated or untreated with SX1 or SX2 was measured by dichloro-dihydro-fluorescein diacetate (DCFH-DA) assay.
Results: SX1 and SX2 MNTDs at concentrations of 1850 nM and 105 nM, respectively, did not significantly (p > 0.05) provide neuroprotection against paraquat-induced SH-SY5Y cell death. Only SX2 MNTD and HMNTD significantly (p < 0.05) protected SH-SH5Y cells against 6-OHDA-induced cell death by 10 and 17 % improved cell viability. Although intracellular ROS production was significantly attenuated by SX1 HMNTD and MNTD, this did not improve cell viability against paraquat-induced cell death.
Conclusion: These results reveal that SX2 confers neuroprotection on 6-OHDA-induced SH-SY5Y neurotoxicity. Further investigations to elucidate the detailed molecular mechanisms of neuroprotection by SX2 are warranted.
Keywords: Prenylation, Xanthone derivatives, Neuroprotection, Paraquat, Dopamine, Neurotoxicity, Human neuroblastoma SH-SY5Y cell, 6-Hydroxydopamine
